Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HY3D
|
|||
| Drug Name |
SY-1425
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | ||
| Company |
Syros Pharmaceuticals Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Retinoic acid receptor alpha (RARA) | Target Info | Agonist | [1] |
| KEGG Pathway | Pathways in cancer | |||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| Pathway Interaction Database | Retinoic acid receptors-mediated signaling | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Vitamin A and Carotenoid Metabolism | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Adipogenesis | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.